Douglas Tsao

Q: How accurate are Douglas Tsao's stock ratings?

About 62% of Douglas's ratings were profitable over a one-year hold, with an average return of +7.9% per rating, measured by 13Foresight from historical prices.

Q: How is Douglas ranked?

Douglas Tsao is ranked #2014 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

H.C. Wainwright

Wall Street Analyst

★★★☆☆

#2014

on 13Foresight · ranked by our own returns

62%

Success Rate

+7.9%

Average Return

63 of 101 calls profitable · +4.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 62% of Douglas Tsao's ratings turned a profit when each position was held for 1 year — averaging +7.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

229 Buy 42 Hold 0 Sell

Douglas's Stock Coverage 44 ratings · 2026-08-27

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
BHVN Biohaven Ltd.	Aug 26, 2026	HOLD	Strong Buy +39.1% avg upside 25 analysts	$10.00 40.91% Downside	·	·
EOLS Evolus	Aug 25, 2026	BUY	Strong Buy +62.7% avg upside 9 analysts	$13.00 48.05% Upside	·	·
NMRA Neumora Therapeutics, Inc.	Aug 24, 2026	BUY	Buy +393.3% avg upside 11 analysts	$7.00 348.76% Upside	·	·
ARGX Argenx Se	Aug 24, 2026	BUY	Strong Buy -20.6% avg upside 47 analysts	$1202.00 14.80% Upside	+1.0%	·
RAPP Rapport Therapeutics, Inc.	Aug 17, 2026	BUY	Strong Buy +12.3% avg upside 14 analysts	$66.00 25.66% Upside	-0.4%	·
AEON AEON Biopharma	Aug 14, 2026	BUY	Strong Buy +337.4% avg upside 2 analysts	$1.20 377.15% Upside	-30.2%	·
DARE Daré Bioscience	Aug 14, 2026	BUY	Strong Buy +1686.8% avg upside 14 analysts	$12.00 1498.75% Upside	-11.7%	·
CRNX Crinetics Pharmaceuticals	Aug 11, 2026	HOLD	Buy -8.7% avg upside 21 analysts	$85.00 0.18% Upside	+0.4%	·
TBPH Theravance Biopharma	Aug 11, 2026	HOLD	Hold +8.3% avg upside 18 analysts	$17.00 0.10% Downside	+0.7%	·
XENE Xenon	Aug 10, 2026	BUY	Strong Buy -2.1% avg upside 28 analysts	$74.00 16.03% Upside	-5.9%	·
PRAX Praxis Precision Medicines	Aug 10, 2026	BUY	Strong Buy +48.1% avg upside 24 analysts	$1201.00 218.29% Upside	+0.3%	·
IRON Disc Medicine	Aug 10, 2026	BUY	Strong Buy +5.9% avg upside 21 analysts	$120.00 45.06% Upside	+1.9%	·
ARQT Arcutis Biotherapeutics	Aug 10, 2026	BUY	Strong Buy +59.7% avg upside 14 analysts	$34.00 35.21% Upside	-3.2%	·
IMVT Immunovant	Aug 10, 2026	BUY	Strong Buy -8.5% avg upside 24 analysts	$41.00 6.54% Downside	+11.2%	·
PTGX Protagonist Therapeutics	Aug 10, 2026	BUY	Strong Buy -20.5% avg upside 19 analysts	$167.00 10.15% Upside	+3.1%	·
NERV Minerva Neurosciences	Aug 10, 2026	HOLD	Strong Buy +56.6% avg upside 8 analysts	$7.00 28.97% Upside	+4.8%	·
ROIV Roivant Sciences	Aug 07, 2026	BUY	Strong Buy -3.3% avg upside 17 analysts	$41.00 11.55% Upside	+0.1%	·
VRDN Viridian Therapeutics	Aug 07, 2026	BUY	Strong Buy +45.7% avg upside 32 analysts	$22.00 9.22% Downside	+1.8%	·
CHRS Coherus Biosciences	Aug 06, 2026	BUY	Buy +771.4% avg upside 18 analysts	$7.00 382.78% Upside	+5.1%	·
PCRX Pacira Pharmaceuticals	Aug 05, 2026	BUY	Buy +52.4% avg upside 21 analysts	$38.00 46.69% Upside	+0.1%	·
ALKS Alkermes	Jul 29, 2026	HOLD	Strong Buy -15.4% avg upside 34 analysts	$43.00 12.44% Downside	-0.8%	·
RZLT Rezolute	Jul 29, 2026	BUY	Strong Buy +112.1% avg upside 13 analysts	$5.00 0.88% Downside	+8.3%	·
OTLK Outlook Therapeutics	Jul 28, 2026	HOLD	Buy +1376.2% avg upside 11 analysts	$1.60 156.69% Upside	-25.2%	·
SE:HNSA Hansa Biopharma AB	Jul 24, 2026	BUY	Strong Buy +221.7% avg upside 4 analysts	$103.00 135.19% Upside	+7.4%	·
CABA Cabaletta Bio	Jun 08, 2026	BUY	Strong Buy +328.7% avg upside 16 analysts	—	-2.2%	·
EVO Evotec AG	Nov 06, 2025	BUY	Buy +330.8% avg upside 9 analysts	$7.00 259.05% Upside	-41.7%	·
TRVN Trevena	Nov 14, 2024	HOLD	Buy +1424900.0% avg upside 11 analysts	$5.00 499900.00% Upside	·	·
RVLPQ RVL Pharmaceuticals	Aug 21, 2023	BUY	Strong Buy +624999900.0% avg upside 6 analysts	$3.00 299999899.93% Upside	·	·
ADOCY Adocia	Apr 21, 2023	HOLD	Hold 1 analyst	—	·	·
CLYM Climb Bio	Mar 08, 2023	HOLD	Strong Buy +16.7% avg upside 19 analysts	$6.00 62.61% Downside	-25.0%	·
TXMD TherapeuticsMD	Nov 30, 2022	HOLD	Buy +173.4% avg upside 8 analysts	—	-43.7%	·
TEVA Teva Pharmaceutical	Aug 06, 2018	HOLD	Buy -19.9% avg upside 39 analysts	$23.00 39.36% Downside	-68.1%	·
PAHC Phibro Animal Health	Jul 03, 2018	SELL	Sell +10.3% avg upside 10 analysts	$33.00 8.59% Downside	+30.5%	·
PRGO Perrigo Company	Jun 06, 2018	HOLD	Buy +363.0% avg upside 20 analysts	$80.00 442.10% Upside	-39.8%	·
TSE:BHC Bausch Health Companies	Jun 06, 2018	BUY	Buy +533.5% avg upside 29 analysts	—	-14.1%	·
AMRX Amneal Pharmaceuticals	May 01, 2018	BUY	Buy +0.4% avg upside 18 analysts	$27.00 50.00% Upside	-15.6%	·
ZTS Zoetis	Feb 16, 2018	HOLD	Buy +53.2% avg upside 23 analysts	$77.00 0.68% Downside	+20.4%	·
IQV IQVIA Holdings	Oct 27, 2017	BUY	Strong Buy -6.3% avg upside 39 analysts	$120.00 54.16% Downside	+11.6%	·
ICLR Icon	Oct 27, 2017	HOLD	Strong Buy +11.5% avg upside 26 analysts	$120.00 29.02% Downside	+14.3%	·
HALO Halozyme	Jun 22, 2017	BUY	Buy -39.6% avg upside 20 analysts	$16.00 84.96% Downside	+22.0%	·
VTRS Viatris	May 22, 2017	BUY	Buy +39.6% avg upside 21 analysts	$50.00 196.76% Upside	+1.5%	·
JAZZ Jazz Pharmaceuticals	Jan 18, 2017	BUY	Strong Buy -4.5% avg upside 35 analysts	$200.00 19.78% Downside	+16.1%	·
CRL Charles River Labs	Nov 30, 2016	HOLD	Strong Buy -20.6% avg upside 35 analysts	—	+46.6%	·
ARCT Arcturus Therapeutics	Nov 16, 2016	SELL	Buy +86.3% avg upside 36 analysts	$2.00 87.41% Downside	+25.9%	·

🔒 39 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Douglas Tsao — Frequently Asked Questions

How accurate are Douglas Tsao's stock ratings?

Based on the calls 13Foresight could measure, about 62% of Douglas's ratings were profitable over a one-year hold, with an average return of +7.9% per rating, or +23.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Douglas ranked on 13Foresight?

Douglas Tsao is currently ranked #2014 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Douglas cover?

Douglas most recently has ratings on BHVN, EOLS, NMRA, ARGX, RAPP, AEON, DARE, CRNX, TBPH, XENE, PRAX, IRON and 32 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Douglas Tsao

Rating Distribution

Welcome to 13Foresight!